Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott D Nelson

Showing results (181-190 of 196) with videos related to

Pageof 20
Sort By:
Journal of Cellular Biochemistry|November 17, 2017
Growth of doxorubicin-resistant undifferentiated spindle-cell sarcoma PDOX is arrested by metabolic targeting with recombinant methioninaseKentaro Igarashi, Shukuan Li, Qinghong Han, et al.
Cancer Letters|January 7, 2018
Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcomaKentaro Igarashi, Kei Kawaguchi, Shukuan Li, et al.
Bone Research|December 11, 2020
Evading the host response: Staphylococcus "hiding" in cortical bone canalicular system causes increased bacterial burdenStephen D Zoller, Vishal Hegde, Zachary D C Burke, et al.
Surgery|October 10, 2025
Dedicated review of sarcoma pathology is necessary for corroborative diagnosis in nearly one half of referred patientsMark A Eckardt, Nicholas M Siena, Amy R Copeland, et al.
Chemotherapy|January 24, 2019
Combining Tumor-Selective Bacterial Therapy with Salmonella typhimurium A1-R and Cancer Metabolism Targeting with Oral Recombinant Methioninase Regressed an Ewing's Sarcoma in a Patient-Derived Orthotopic Xenograft ModelKentaro Miyake, Tasuku Kiyuna, Shukuan Li, et al.
Oncotarget|May 4, 2018
Recombinant methioninase combined with doxorubicin (DOX) regresses a DOX-resistant synovial sarcoma in a patient-derived orthotopic xenograft (PDOX) mouse modelKentaro Igarashi, Kei Kawaguchi, Shukuan Li, et al.
Cell Cycle (Georgetown, Tex.)|January 30, 2018
Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatinum eradicates an osteosarcoma cisplatinum-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinicKentaro Igarashi, Kei Kawaguchi, Tasuku Kiyuna, et al.
JAMA Network Open|December 17, 2025
Five-Day Preoperative Radiation Therapy for Patients With High-Risk Soft Tissue Sarcoma: A Nonrandomized Clinical TrialJohn Nikitas, Joseph K Kendal, Ricky R Savjani, et al.
Biochemical and Biophysical Research Communications|September 1, 2018
Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanomaKei Kawaguchi, Takashi Higuchi, Shukuan Li, et al.
Biochemical and Biophysical Research Communications|October 8, 2018
A combination of irinotecan/cisplatinum and irinotecan/temozolomide or tumor-targeting Salmonella typhimurium A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse modelTasuku Kiyuna, Yasunori Tome, Takashi Murakami, et al.
Pageof 20

Showing results (181-190 of 196) with videos related to

Sort By:
Pageof 20
Journal of Cellular Biochemistry|November 17, 2017
Growth of doxorubicin-resistant undifferentiated spindle-cell sarcoma PDOX is arrested by metabolic targeting with recombinant methioninaseKentaro Igarashi, Shukuan Li, Qinghong Han, et al.
Cancer Letters|January 7, 2018
Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcomaKentaro Igarashi, Kei Kawaguchi, Shukuan Li, et al.
Bone Research|December 11, 2020
Evading the host response: Staphylococcus "hiding" in cortical bone canalicular system causes increased bacterial burdenStephen D Zoller, Vishal Hegde, Zachary D C Burke, et al.
Surgery|October 10, 2025
Dedicated review of sarcoma pathology is necessary for corroborative diagnosis in nearly one half of referred patientsMark A Eckardt, Nicholas M Siena, Amy R Copeland, et al.
Chemotherapy|January 24, 2019
Combining Tumor-Selective Bacterial Therapy with Salmonella typhimurium A1-R and Cancer Metabolism Targeting with Oral Recombinant Methioninase Regressed an Ewing's Sarcoma in a Patient-Derived Orthotopic Xenograft ModelKentaro Miyake, Tasuku Kiyuna, Shukuan Li, et al.
Oncotarget|May 4, 2018
Recombinant methioninase combined with doxorubicin (DOX) regresses a DOX-resistant synovial sarcoma in a patient-derived orthotopic xenograft (PDOX) mouse modelKentaro Igarashi, Kei Kawaguchi, Shukuan Li, et al.
Cell Cycle (Georgetown, Tex.)|January 30, 2018
Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatinum eradicates an osteosarcoma cisplatinum-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinicKentaro Igarashi, Kei Kawaguchi, Tasuku Kiyuna, et al.
JAMA Network Open|December 17, 2025
Five-Day Preoperative Radiation Therapy for Patients With High-Risk Soft Tissue Sarcoma: A Nonrandomized Clinical TrialJohn Nikitas, Joseph K Kendal, Ricky R Savjani, et al.
Biochemical and Biophysical Research Communications|September 1, 2018
Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanomaKei Kawaguchi, Takashi Higuchi, Shukuan Li, et al.
Biochemical and Biophysical Research Communications|October 8, 2018
A combination of irinotecan/cisplatinum and irinotecan/temozolomide or tumor-targeting Salmonella typhimurium A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse modelTasuku Kiyuna, Yasunori Tome, Takashi Murakami, et al.
Pageof 20